PerpEquities

WuXi Biologics (Cayman) Inc. (WUXIBIO) financials

HKSE · Healthcare · Biotechnology · 14,705 employees · CEO Zhisheng Chen

Price
HK$44.60 +0.27%
Market cap
HK$184B
Enterprise value
CN¥149B
Last report
Q2 '26 filed 2026-06-30
Next report
2027-03-23
Revenue (TTM)CN¥23.6B+17.8% vs a year agoLast 2 half-years; bars = each half-year
Operating margin (TTM)32.4%+3.0 pp vs a year agoOperating income CN¥7.64B
Net income (TTM)CN¥5.01B+19.4% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)CN¥4.42B+151.5% vs a year agoCapex CN¥4.63B
Diluted EPS (TTM)CN¥1.19+21.4% vs a year agoSum of the last 2 half-years
Net cashCN¥10.3B+58.9% vs a year agoCash + short-term investments - debt

Valuation & key figures

Market cap
HK$184B
EV CN¥149B
Revenue
CN¥23.6B
Trailing 12 months
Revenue growth
+20%
FY2026 consensus
Profit margin
21.2%
Net income / revenue, TTM
P/E
31.2×
P/S
6.6×
Price / sales, TTM
EV / EBITDA
15.8×
TTM
Free cash flow
CN¥4.42B
Trailing 12 months
Net income
CN¥5.01B
Trailing 12 months
Revenue estimate
CN¥26.1B
FY2026 consensus
Earnings
2027-03-23
Dividend
–
No dividend

Key takeaways

Computed from the reported numbers - every statement carries the figure it rests on.

  • Revenue growth accelerating: 18.4% year on yearQ2 '26 revenue CN¥11.8B, against an average of 13.1% over the four half-years before.
  • Operating margin 32.4% (TTM), +3.0 pp on a year agoOperating income grew 30.0% while revenue grew 17.8%.
  • Capex 19.6% of revenue (a year ago 19.8%)CN¥4.63B invested in the last 2 half-years (+16.8% on a year earlier). Free cash flow CN¥4.42B = 88.3% of net income.
  • Returned CN¥1.86B to shareholders = 42.1% of free cash flowBuybacks CN¥1.86B (a year earlier CN¥1.56B), dividends CN¥0, stock-based pay CN¥455M (TTM).
  • Diluted share count down 0.1% in a year4.18B diluted shares in Q2 '26, 4.19B a year earlier.
  • Net cash CN¥10.3BCash + short-term investments CN¥13B, debt incl. leases CN¥2.73B; a year ago net cash CN¥6.49B.

Last quarter: Q2 '26

Quarter ended 2026-06-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.

Quarter vs a year ago

Q2 '26Year agoChange
RevenueCN¥11.8BCN¥9.95B+18.4%
Gross margin46.2%42.7%+3.5 pp
Operating incomeCN¥3.73BCN¥2.72B+36.8%
Operating margin31.6%27.4%+4.3 pp
Net incomeCN¥2.44BCN¥2.34B+4.3%
Diluted EPSCN¥0.58CN¥0.55+5.5%
Operating cash flowCN¥4.46BCN¥1.81B+146.6%
CapexCN¥2.82BCN¥1.9B+48.5%
Free cash flowCN¥1.63B-CN¥93.7M+1,844.6%
R&DCN¥424MCN¥344M+23.5%
Stock-based compensationCN¥455MCN¥469M-3.0%

Revenue

Where the money comes from - by business line and by region, quarter by quarter.

Revenue, operating income and growth

quarterly

Margins & cost structure

How much of each unit of revenue is left at each level - and where the costs go.

Margins

quarterly

Costs as % of revenue

quarterly

Cash flow & capital allocation

Cash generated, what it is spent on, and what reaches shareholders.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Last 2 half-years

cash flow statement
Operating cash flow
CN¥9.05B
Capex
-CN¥4.63B
Buybacks
-CN¥1.86B
Dividends
CN¥0
Acquisitions
CN¥1.28B
Net debt issued
-CN¥2.4B
Stock-based compensation
CN¥455M
Free cash flow
CN¥4.42B
Returned to shareholders / FCF
42.1%

Share count and EPS

quarterly, diluted

Balance sheet

Liquidity, investments and debt at each quarter end.

Cash, investments and debt

quarter ends

Valuation & returns

Today's multiples against the company's own last five fiscal years; analyst targets and ratings.

Multiples and returns

TTM vs 5 fiscal years
Now5y averageWhere today sits in the 5-year range
P/E (TTM)31.2×43.8×20.1× – 93.1×
EV / EBITDA15.8×29.9×10.0× – 72.4×
EV / Sales6.3×12.1×3.4× – 31.8×
Price / FCF35.2×114.0× 3 of 5 years42.1× – 247.7×
Price / Book3.2×4.7×1.6× – 10.3×
FCF yield2.8%0.7%-0.9% – 2.4%
Return on invested capital10.6%8.2%7.4% – 9.3%
Return on equity10.5%10.0%8.0% – 12.6%

Outlook

Analyst consensus for the coming fiscal years and what it implies at today's price.

Consensus estimates

Fiscal yearRevenueGrowthEPSGrowthP/E at today's priceAnalysts (EPS)
FY2026CN¥26.1B+20.0%CN¥1.44+24.1%–16
FY2027CN¥31.4B+20.1%CN¥1.79+24.2%–17
FY2028CN¥37.7B+20.1%CN¥2.19+22.4%–17
FY2029CN¥43.1B+14.4%CN¥2.63+20.1%–12
FY2030CN¥50.1B+16.2%CN¥3.08+17.1%–7

Financial statements

Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.

Income statementRevenue, costs, operating income, net income and EPSOpenBalance sheetCash, investments, assets, debt, liabilities and equityOpenCash flowOperating cash flow, capex, free cash flow, buybacks and dividendsOpen

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-02 · Amounts in CNY as reported; price and market cap in HKD.